Biotechnology: FDA Leadership Transition: Stepping In as Acting Commissioner

Research evidence excerpt

Biotechnology: FDA Leadership Transition: Stepping In as Acting Commissioner

Update

May 13, 2026 06:18 PM GMT

Morgan Stanley & Co. LLCMBiotechnology | North America Sean Laaman, Ph.D.

Equity Analyst

FDA Leadership Transition: Sean.Laaman@morganstanley.comKatherine Sun +1 212 761-4947

Research Associate

Katherine.Sun@morganstanley.com +1 212 761-5968

Stepping In as Acting Michael H Riad, Ph.D.

Michael.Riad@morganstanley.com +1 212 761-1309

Commissioner Morgan K Gryga

Morgan.Gryga@morganstanley.com +1 212 761-0824

Policy-driven FDA leadership raises variability at the margin: base

Biotechnology

timelines intact, but higher risk for CNS, rare disease, and novel North America

modalities. Oncology least impacted. Net: wider approval Industry View Attractive

outcomes → higher regulatory risk premium for SMID biotech.

Key Takeaways

Biotechnology regulation may face higher near-term uncertainty as acting

leadership shifts toward policy/legal coordination while CDER/CBER autonomy

persists.

FDA Leadership Transition: Kyle Diamantas Steps In as Acting Commissioner:

Following the May 12, 2026 resignation of FDA Commissioner Marty Makary, Kyle

Diamantas has been appointed Acting Commissioner.

Diamantas is not a traditional FDA commissioner in profile: A trained attorney

rather than a physician or scientist, he previously served as the FDA’s Deputy

Commissioner for Food, where he led the agency’s Human Foods Program and

oversaw nationwide food safety, nutrition policy, inspections, and enforcement

activities. Prior to joining the FDA, he was a partner at Jones Day, advising food and

beverage companies on regulatory and compliance matters, giving him deep

familiarity with FDA legal frameworks and industry engagement.